NASDAQ:NRBO NeuroBo Pharmaceuticals 8/14/2024 Earnings Report $1.50 +0.80 (+115.55%) As of 09/15/2025 ProfileEarnings History NeuroBo Pharmaceuticals EPS ResultsActual EPS-$1.85Consensus EPS -$1.38Beat/MissMissed by -$0.47One Year Ago EPSN/ANeuroBo Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuroBo Pharmaceuticals Announcement DetailsQuarterDate8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsNeuroBo Pharmaceuticals' next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile NeuroBo Pharmaceuticals Earnings HeadlinesMTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comNeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century. | Banyan Hill Publishing (Ad)NeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comSee More NeuroBo Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroBo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroBo Pharmaceuticals and other key companies, straight to your email. Email Address About NeuroBo PharmaceuticalsNeuroBo Pharmaceuticals (NASDAQ:NRBO) (NASDAQ: NRBO) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for central nervous system (CNS) disorders and acute neurological injuries. Utilizing a proprietary target discovery platform that integrates bioinformatics, multi-omics analyses and functional screening, the company identifies key drivers of neuronal damage and repair. Its lead candidate, NB-01, is a humanized monoclonal antibody targeting pathways involved in neuroinflammation and axonal growth, currently in Phase 1b clinical trials for acute ischemic stroke. Beyond NB-01, the NeuroBo pipeline includes preclinical programs such as NB-02, which seeks to address neuropathic pain through modulation of P2X ion channels, and NB-03, aimed at slowing progression in certain neurodegenerative diseases. The company leverages partnerships with academic institutions and research centers to enhance its discovery capabilities and accelerate preclinical candidate selection. Its platform approach enables rapid validation of novel targets and the development of biologics with potential applications across a range of CNS indications. Headquartered in Cambridge, Massachusetts, NeuroBo Pharmaceuticals serves patients globally through collaborative research and development efforts in North America and Asia. The company is led by an experienced team of neuroscientists and biotech executives dedicated to advancing new treatments for unmet needs in neurology. Through its integrated discovery and development model, NeuroBo seeks to translate scientific insights into transformative therapies for individuals affected by central nervous system disorders.View NeuroBo Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
